SEC 13F Intelligence

Managers / Q1 2021 · view latest →

FRAZIER MANAGEMENT LLC

CIK 0001032165 · 601 UNION ST, SUITE 2110, SEATTLE, WA, 98101 · 2066217200

Reported Value
$1.2B
Q1 2021
Positions
35
Filings on Record
16
2019–present window
Filed
May 12, 2021
original filing

Summary

Frazier Management LLC reported $1.2B in U.S.-listed holdings across 35 positions for Q1 2021.

The portfolio is heavily concentrated: ARQT alone accounts for 24.5% of reported value.

Compared with Q4 2020, the fund opened 4 new positions and exited 4.

Portfolio Metrics

Turnover
+8.9%
vs prior filed quarter
Top-10 Concentration
+77.8%
share of reported value
Largest Position
+24.5%
Arcutis Biotherapeutics
New / Exited
4 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $388MQ4 ’18Q1 ’19: $415MQ2 ’19: $390MQ2 ’19Q3 ’19: $320MQ4 ’19: $596MQ4 ’19Q1 ’20: $882MQ2 ’20: $1.1BQ2 ’20Q3 ’20: $1.1BQ4 ’20: $1.3BQ4 ’20Q1 ’21: $1.2BQ2 ’21: $1.1BQ2 ’21Q3 ’21: $1.2BQ4 ’21: $1.3BQ4 ’21Q2 ’22: $1MQ3 ’22: $0Q3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 83.4%Other: 16.6%
  • Common Stock · 83.4% · $1.0B
  • Other · 16.6% · $207M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ACRSACLARIS THERAPEUTICS INCNEW+696.0K696.0K+$18M$18M
ESSA PHARMA INCNEW+316.6K316.6K+$9M$9M
IMVTIMMUNOVANT INCNEW+508.0K508.0K+$8M$8M
AVADEL PHARMACEUTICALS PLCNEW+578.1K578.1K+$5M$5M
COLLCOLLEGIUM PHARMACEUTICAL INCSOLD OUT−943.7K0−$19M$0
RCKTROCKET PHARMACEUTICALS INCSOLD OUT−168.0K0−$9M$0
SPRYSILVERBACK THERAPEUTICS INCSOLD OUT−35.8K0−$2M$0
MINERVA NEUROSCIENCES INCSOLD OUT−61.5K0−$144,000$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2021

35 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM24.46%$305M10.54M
2PHATPHATHOM PHARMACEUTICALS INChistory →COM17.56%$219M5.83M
3PASSAGE BIO INCCOM7.02%$88M5.01M
4MIRMMIRUM PHARMACEUTICALS INChistory →COM5.67%$71M3.57M
5KRYSKRYSTAL BIOTECH INChistory →COM5.53%$69M895.0K
6TARSTARSUS PHARMACEUTICALS INChistory →COM4.96%$62M1.92M
7PCVXVAXCYTE INChistory →COM3.66%$46M2.31M
8IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM3.33%$42M1.31M
9TRANSLATE BIO INCCOM2.89%$36M2.18M
10TREURTRILLIUM THERAPEUTICS INChistory →COM NEW2.68%$33M3.12M
11SNDXSYNDAX PHARMACEUTICALS INChistory →COM2.57%$32M1.44M
12ALPINE IMMUNE SCIENCES INCCOM2.19%$27M2.57M
13SUTRO BIOPHARMA INCCOM1.83%$23M1.00M
14ANABANAPTYSBIO INChistory →COM1.56%$19M899.7K
15ACRSACLARIS THERAPEUTICS INChistory →COM1.41%$18M696.0K
16MOLECULAR TEMPLATES INCCOM1.39%$17M1.37M
17IVERIC BIO INCCOM1.26%$16M2.54M
18FRAZIER LIFESCIENCES ACQU COUNIT 12/09/20251.22%$15M1.50M
19ADVERUM BIOTECHNOLOGIES INCCOM1.14%$14M1.44M
20RGNXREGENXBIO INChistory →COM0.96%$12M352.0K
21GRITSTONE ONCOLOGY INCCOM0.78%$10M1.03M
22APTINYX INCCOM0.77%$10M3.19M
23ESSA PHARMA INCCOM NEW0.74%$9M316.6K
24IMVTIMMUNOVANT INCCOM0.65%$8M508.0K
25SRRKSCHOLAR ROCK HLDG CORPCOM0.63%$8M156.0K
26FREELINE THERAPEUTICS HLDGSSPONSORED ADS0.54%$7M550.0K
27EPIZYME INCCOM0.52%$6M739.4K
28AVADEL PHARMACEUTICALS PLCSPONSORED ADR0.42%$5M578.1K
29BLUBELLUS HEALTH INC NEWCOM NEW0.40%$5M1.30M
30ALLENA PHARMACEUTICALSCOM0.37%$5M3.33M
31SIERRA ONCOLOGY INCCOM NEW0.28%$3M202.8K
32CRDFCARDIFF ONCOLOGY INCCOM0.22%$3M293.5K
33ITERUM THERAPEUTICS PLCSHS0.17%$2M1.54M
34GRTXGALERA THERAPEUTICS INCCOM0.17%$2M241.0K
35NABRIVA THERAPEUTICS PLCSHS0.06%$707,000425.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$01Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1M1Aug 10, 202213F-HRchanges · EDGAR ↗
Q1 2022Under review2May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.3B43Feb 8, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B41Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.1B34Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.2B35May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.3B35Feb 11, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.1B31Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B26Aug 4, 202013F-HRchanges · EDGAR ↗
Q1 2020$882M25May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$596M20Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$320M19Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$390M18Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$415M17May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$388M17Feb 11, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.